Skip to main content

Table 3 Risk factors for adverse events due to diarrhoea or vomiting within 28 days following therapy

From: Safety and tolerability of artemether-lumefantrine versus dihydroartemisinin-piperaquine for malaria in young HIV-infected and uninfected children

Risk category

Risk group

Diarrhoea

Vomiting

  

AL

DP

AL

DP

  

HR† (95% CI)

p-value

HR† (95% CI)

p-value

HR† (95% CI)

p-value

HR† (95% CI)

p-value

Age

>15-22 months

1.0 (reference)

-

1.0 (reference)

-

1.0 (reference)

-

1.0 (reference)

-

 

>12-15 months

1.17 (0.56-2.46)

0.67

3.34 (1.39-8.02)

0.007

0.75 (0.10-5.58)

0.78

2.66 (0.80-8.85)

0.11

 

>10-12 months

2.04 (1.09-3.85)

0.03

4.03 (1.90-8.53)

< 0.001

0.32 (0.04-2.86)

0.31

2.61 (0.66-10.3)

0.17

 

4-10 months

2.11 (1.09-4.08)

0.03

3.22 (1.33-7.81)

0.01

1.14 (0.30-4.27)

0.84

1.08 (0.20-5.90)

0.93

Duration since last treatment

> 63 days or no prior treatment

1.0 (reference)

-

1.0 (reference)

-

1.0 (reference)

-

1.0 (reference)

-

 

28-63 days

0.54 (0.34-0.86)

0.009

0.85 (0.47-1.52)

0.57

0.77 (0.24-2.42)

0.65

0.78 (0.30-2.02)

0.60

 

17-28 days

0.68 (0.36-1.29)

0.24

1.33 (0.47-3.73)

0.59

0.71 (0.11-4.73)

0.72

6.63 (2.33-18.9)

< 0.001

HIV status,

HIV-uninfected not taking TS

1.0 (reference)

-

1.0 (reference)

-

1.0 (reference)

-

1.0 (reference)

-

TS use,

HIV-uninfected taking TS

0.78 (0.47-1.28)

0.32

1.26 (0.76-2.11)

0.37

1.04 (0.27-4.02)

0.95

1.30 (0.47-3.55)

0.62

ARV use*

HIV-infected taking TS and ARVs

0.33 (0.12-0.90)

0.03

0.46 (0.11-2.03)

0.31

1.77 (0.20-15.7)

0.61

1.85 (0.31-10.9)

0.50

  1. † HR = hazard ratio, generated using multivariate Cox proportional hazard models adjusted for repeated measures in the same patient
  2. * HIV-infected patients not taking ARVs not included in the analysis due to small numbers (n = 16)